Keros Therapeutics (KROS) announced that, as part of its previously announced $375M capital return program, it has commenced a cash tender offer to repurchase up to $194.4M of shares of the company’s common stock, subject to market conditions, at a purchase price of $17.75 per share. The company expects to fund the tender offer from its existing cash and cash equivalents. The tender offer will expire at 5:00 p.m. ET on Tuesday, November 18, unless extended or earlier terminated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics Announces $375M Capital Return Program
- Keros Therapeutics announces share repurchase program
- Keros Therapeutics Presents Promising Phase 1 Trial Data
- Keros Therapeutics presents additional clinical data from KER-065 program
- Keros Therapeutics CEO to Speak at Healthcare Conferences